Compare CAPR & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | GILT |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2011 | 1997 |
| Metric | CAPR | GILT |
|---|---|---|
| Price | $30.60 | $17.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $41.38 | $20.00 |
| AVG Volume (30 Days) | 921.3K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,270,465.00 | N/A |
| Revenue This Year | N/A | $15.06 |
| Revenue Next Year | $17,308.50 | $11.72 |
| P/E Ratio | ★ N/A | $42.82 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $5.30 |
| 52 Week High | $40.37 | $20.38 |
| Indicator | CAPR | GILT |
|---|---|---|
| Relative Strength Index (RSI) | 66.95 | 56.16 |
| Support Level | $22.09 | $13.11 |
| Resistance Level | $40.37 | $20.38 |
| Average True Range (ATR) | 1.84 | 0.86 |
| MACD | 0.17 | 0.19 |
| Stochastic Oscillator | 92.68 | 86.62 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.